13 Best Long-Term Penny Stocks to Buy According to Analysts

Page 5 of 12

8. ImmunityBio Inc. (NASDAQ:IBRX)

Stock Price: $2.84

Analyst Upside: 181.69%

Number of Hedge Fund Holders: 10

ImmunityBio Inc. (NASDAQ:IBRX) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts. On June 2, ImmunityBio Inc. (NASDAQ:IBRX) announced that it attained Expanded Access authorization from the U.S. Food and Drug Administration, FDA, for its Cancer BioShield platform, anchored by ANKTIVA, to treat lymphopenia, a life-threatening immune deficiency induced by radiotherapy, chemotherapy, and immunotherapy.

The Expanded Access covers all patients with solid tumors who failed first-line treatment on radiotherapy, immunotherapy, or chemotherapy, and exhibit low Absolute Lymphocyte Counts (ALC <1,000/μL).

On June 4, H.C. Wainwright analyst Andres Y. Maldonado maintained a Buy rating on ImmunityBio Inc. (NASDAQ:IBRX) and set a price target of $8.00, highlighting the company’s innovative approach to the treatment of lymphopenia.

He supported the optimistic outlook with ImmunityBio Inc.’s (NASDAQ:IBRX) Cancer BioShield platform, including ANKTIVA and PD-L1 t-haNK CAR-NK cells, citing that it attained notable regulatory milestones, such as an Expanded Access authorization from the FDA and RMAT designation. These milestones reflect the potential of the company’s therapies in complicated cancer cases.

ImmunityBio, Inc. (NASDAQ:IBRX) is a clinical-stage immunotherapy company that develops next-generation therapies to treat cancer and infectious diseases. Its immunotherapy platform activates the adaptive and innate immune systems to create long-term immunological memory.

Page 5 of 12